SG11202108648TA - 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative - Google Patents

7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative

Info

Publication number
SG11202108648TA
SG11202108648TA SG11202108648TA SG11202108648TA SG11202108648TA SG 11202108648T A SG11202108648T A SG 11202108648TA SG 11202108648T A SG11202108648T A SG 11202108648TA SG 11202108648T A SG11202108648T A SG 11202108648TA SG 11202108648T A SG11202108648T A SG 11202108648TA
Authority
SG
Singapore
Prior art keywords
pyrrolo
pyrimidine
amine derivative
amine
derivative
Prior art date
Application number
SG11202108648TA
Other languages
English (en)
Inventor
Fuyuki Yamamoto
Takashi Mizutani
Hidefumi Kasuga
Hirokazu Fuchida
Shoki Hara
Yu KOBAYAKAWA
Yoshio Ogino
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of SG11202108648TA publication Critical patent/SG11202108648TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202108648TA 2019-02-15 2020-02-14 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative SG11202108648TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019025844 2019-02-15
PCT/JP2020/005684 WO2020166680A1 (ja) 2019-02-15 2020-02-14 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－アミン誘導体

Publications (1)

Publication Number Publication Date
SG11202108648TA true SG11202108648TA (en) 2021-09-29

Family

ID=72044229

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108648TA SG11202108648TA (en) 2019-02-15 2020-02-14 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative

Country Status (13)

Country Link
US (1) US11786534B2 (ja)
EP (1) EP3925669A4 (ja)
JP (1) JP6960064B2 (ja)
KR (1) KR102645237B1 (ja)
CN (1) CN113453764B (ja)
AU (1) AU2020221744B2 (ja)
BR (1) BR112021015813A2 (ja)
CA (1) CA3130049C (ja)
MA (1) MA54960A (ja)
MX (1) MX2021009752A (ja)
SG (1) SG11202108648TA (ja)
TW (1) TWI828861B (ja)
WO (1) WO2020166680A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023204303A1 (ja) * 2022-04-22 2023-10-26 大鵬薬品工業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－アミン誘導体の結晶
TW202400139A (zh) * 2022-04-22 2024-01-01 日商大鵬藥品工業股份有限公司 ７Ｈ－吡咯［２，３－ｄ〕嘧啶－４－胺衍生物之製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007075554A2 (en) 2005-12-19 2007-07-05 Osi Pharmaceuticals, Inc. Combination of igfr inhibitor and anti-cancer agent
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2013118817A1 (ja) 2012-02-07 2013-08-15 大鵬薬品工業株式会社 キノリルピロロピリミジン化合物又はその塩
AU2013344656A1 (en) 2012-11-15 2015-06-04 Pharmacyclics Llc Pyrrolopyrimidine compounds as kinase inhibitors
EP3145512B1 (en) 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20

Also Published As

Publication number Publication date
JP6960064B2 (ja) 2021-11-05
JPWO2020166680A1 (ja) 2021-11-04
CA3130049A1 (en) 2020-08-20
CA3130049C (en) 2024-04-16
AU2020221744A1 (en) 2021-09-23
TWI828861B (zh) 2024-01-11
KR102645237B1 (ko) 2024-03-07
EP3925669A4 (en) 2022-10-26
EP3925669A1 (en) 2021-12-22
MX2021009752A (es) 2021-09-08
KR20210116598A (ko) 2021-09-27
CN113453764B (zh) 2024-04-16
MA54960A (fr) 2021-12-22
US11786534B2 (en) 2023-10-17
CN113453764A (zh) 2021-09-28
AU2020221744B2 (en) 2022-06-23
US20220160719A1 (en) 2022-05-26
WO2020166680A1 (ja) 2020-08-20
TW202045509A (zh) 2020-12-16
BR112021015813A2 (pt) 2021-10-13

Similar Documents

Publication Publication Date Title
HK1258157A1 (zh) 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物
IL267979A (en) Pyrrolo[1,2-B]pyridazine derivatives
HK1256751A1 (zh) [1，2，4]三唑並[1，5-a]嘧啶-7-基化合物
EP3543242A4 (en) 8,9-DIHYDROIMIDAZOLE [1,2-A] PYRIMIDO [5,4-E] PYRIMIDINE-5 (6H) KETONE COMPOUND
IL285311A (en) Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists
EP3508487A4 (en) PYRAZOLO [1,5-a] PYRIMIDINE COMPOUND
IL290445A (en) [4,2,1]triazolo[5,1-c]quinazoline-5-amines
ZA202100259B (en) Pyrrolo[1,2-b]pyridazine derivatives
EP3196199A4 (en) Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
HK1259613A1 (zh) 新型5h-吡咯並[2，3-d]嘧啶-6(7h)-酮衍生物
SG11202108648TA (en) 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative
EP3475286A4 (en) USE OF PYRROLO [2,3-D] PYRIDAZIN-4-ONES AND PYRAZOLO [3,4-D] PYRIDAZIN-4-ONES COMPOUNDS SUBSTITUTED AS INHIBITORS OF PROTEIN KINASES
HK1257427A1 (zh) 用於製備2-吡唑並[1，5-a]吡嗪-2-基吡啶並[1，2-a]嘧啶-4-酮的方法